The compound was discovered and initially developed by Stony Brook University’s Iwao Ojima, PhD, and Martin Kaczocha, PhD.

慢加急性肝衰竭（ACLF）是指在慢性肝病基础上出现的急性肝功能恶化，以肝内肝外器官衰竭和高病死率为主要特征的临床综合征。肝衰竭的发病机制复杂，相关生物标志物的探索有助于预测疾病的转归。免疫和炎症相关指标［可溶性CD163（sCD163）、可溶性甘露糖 ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Progression to the next cohort marks a major milestone in the development of Fatty Acid Binding Protein (FABP) inhibitors as a novel treatment approach for a large number of potential indications.

ART26.12 is the lead compound in Artelo's proprietary Fatty Acid Binding Protein (FABP) platform and is believed to be the first-ever selective FABP5 inhibitor to enter clinical trials.

Figure 1. Relationships between MAFLD and metabolic disorders that increase cardiovascular risk. The association between MAFLD and renal dysfunction is intriguing and has been highlighted in recent ...